Projenx Inc.
NY
- UEI
- TJLMX6EDJ8W9
- CAGE
- 9Y6A4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 45-18 Ct Square E, Long Island City, NY 11101, USA
- Website
- projenx.com
- Founded
- 2021
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A phase 1C study of prosetin, a novel, brain-penetrant MAP4K inhibitor, in participants with ALS | Defense Health Agency | $2,180,261 |
Quick answers
What is Projenx Inc.'s UEI?
Projenx Inc.'s Unique Entity ID (UEI) in SAM.gov is TJLMX6EDJ8W9.
What is Projenx Inc.'s CAGE code?
Projenx Inc.'s CAGE code is 9Y6A4.
What is Projenx Inc.'s primary NAICS code?
Projenx Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Projenx Inc. located?
Projenx Inc.'s physical address in SAM.gov is 45-18 Ct Square E, Long Island City, NY 11101, USA.
Is Projenx Inc. registered in SAM.gov?
Yes. Projenx Inc.'s SAM.gov registration is active through July 28, 2027.
What is Projenx Inc.'s most recent federal award?
Projenx Inc.'s most recent federal grant award is A phase 1C study of prosetin, a novel, brain-penetrant MAP4K inhibitor, in participants with ALS (HT94252510185), from Defense Health Agency, on April 1, 2025.
On GovTribe
See Projenx Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors